Compositions for the prevention or treatment of pulmonary fibrosis

Abstract

A composition for preventing or treating pulmonary fibrosis, comprising ginseng, amomum villosum, poria cocos, tangerine peel, honeysuckle flower and licorice.

Description

Technical Field

[0001] This invention relates to a traditional Chinese medicine composition, specifically a composition for the prevention or treatment of pulmonary fibrosis. Background Technology

[0002] For thousands of years, traditional Chinese medicine has accumulated rich experience in understanding epidemics through continuous practice, gradually forming a relatively complete theoretical system. Although the novel coronavirus infection (SARS-CoV-2) is not recorded in ancient Chinese medical books, some scholars consider it typhoid fever, while others consider it febrile disease; in short, it falls under the category of exogenous diseases in Chinese medicine. According to the "Ling Shu: The Origin of All Diseases," "Wind, rain, cold, and heat cannot harm a person without a deficiency… This must be due to the wind of deficiency and the body's constitution; when both are deficient, the pathogenic factors will stagnate in the body and cause disease." The onset of exogenous diseases requires two essential conditions: first, the pathogenic wind (one of the six evil qi), and second, the deficiency of the body's vital energy (the second deficiency). Hence, it is said that when the two deficiencies meet, the pathogenic wind will stagnate in the body and cause disease. Therefore, we believe that the pathogenesis of novel coronavirus infection is related to two aspects: one is the invasion of the six evil qi. The *Suwen* (Plain Questions) chapter "On the Essential Principles of Medicine" states: "The origin of all diseases lies in the transformation and changes caused by wind, cold, summer heat, dampness, dryness, and fire." All exogenous diseases are caused by the six pathogenic factors: wind, cold, summer heat, dampness, dryness, and fire, also known as "external evils." The current outbreak of the novel coronavirus occurred in winter, a time of cold weather, abundant rainfall, and high humidity in the affected areas; dampness, cold, and rain are its climatic characteristics. The highest proportion of patients presented with cold-dampness obstructing the lungs. Therefore, we believe that the initial stage of this disease is mainly caused by the invasion of dampness and cold pathogens into the body. Cold is a yin evil, easily damaging yang qi. Its stagnant nature impairs the body's lung and defensive qi. The lungs govern qi, and their functions of dispersing and descending qi are disrupted, hence symptoms such as fever, chills, cough, and shortness of breath. Dampness is also a yin evil, heavy and turbid, easily damaging spleen yang. The spleen's function of transportation and transformation is disrupted, hence symptoms such as loss of appetite, fatigue, nausea, vomiting, constipation, and diarrhea. Furthermore, the spleen is the source of phlegm production, and the lungs are the receptacle for phlegm. The ground-glass opacities on early lung CT scans of patients infected with the novel coronavirus, and the subsequent development of "white lung," are closely related to the dysfunction of both the lungs and spleen. Based on the frequency distribution of symptoms, it can be concluded that most cases initially present with superficial or semi-superficial / semi-interior syndromes. If the exterior is not relieved and cold is not dispelled, and the spleen is not strengthened and dampness eliminated in time, as the disease progresses or the patient's constitution varies, the pathogenic factors will penetrate deeper, leading to cold-dampness obstructing the lungs. Dampness transforming into heat results in damp-heat syndrome; heat toxins entering the interior and invading the lung and wei qi result in epidemic toxins obstructing the lungs; invading the qi and ying qi results in qi and ying qi burning simultaneously; when pathogenic factors are trapped internally, both qi and yin are damaged, yin fluids are severely deficient, and yang qi collapses, resulting in internal obstruction and external collapse syndrome. Secondly, deficiency of vital qi and dysfunction of wei qi are also factors. The *Suwen* (Plain Questions) states, "When vital qi is abundant internally, pathogenic factors cannot invade…avoid the toxic qi." The *Suwen* also states, "Avoid pathogenic factors and harmful winds at appropriate times." Regarding exogenous diseases, the *Huangdi Neijing* not only emphasizes the importance of preserving the body's vital energy, but also attaches great importance to avoiding external pathogenic factors. The *Lingshu* chapter "Prohibitions on Clothing" states, "Examine the defensive qi, for it is the mother of all diseases," and the *Shangge* chapter further states, "If the defensive qi does not circulate, pathogenic factors will reside there."It is evident that Wei Qi, as a defensive substance used by the body to fight against pathogenic factors, plays a crucial role in the occurrence and development of diseases. Its strength or weakness is an internal cause of disease and determines the strength or weakness of pathogenic factors and the turning point of the disease. As Zhang Xichun stated, "If Wei Qi is abundant, it can act as an external barrier for the whole body, preventing wind from entering." In other words, without a strong Wei Qi, external pathogenic factors cannot arise. Therefore, the primary task of prevention must be to preserve and enhance the body's vital energy. Summary of the Invention

[0003] Based on the pathogenesis and pathological characteristics of viral pneumonia, especially novel coronavirus infection, and in accordance with the principles of syndrome differentiation and treatment in traditional Chinese medicine, this invention formulates a prescription using food and medicine homology, specifically providing a prescription for the prevention of novel coronavirus infection. Furthermore, through research on pulmonary fibrosis patterns, this invention unexpectedly discovered that this prescription can be used for the prevention or treatment of pulmonary fibrosis.

[0004] On one hand, the present invention provides a composition comprising the following ingredients: ginseng, amomum villosum, poria cocos, tangerine peel, honeysuckle, and licorice.

[0005] Formulas for preventing novel coronavirus infection:

[0006] 1. Ginseng: Taste and nature: sweet and slightly bitter; warm and neutral. Meridians: Spleen and Lung. Functions: Greatly replenishes vital energy, restores pulse and consolidates the body, strengthens the spleen and lungs, generates fluids, and calms the mind. Indications: Physical weakness and impending collapse, cold limbs and weak pulse, spleen deficiency with poor appetite, lung deficiency with cough and asthma, thirst due to fluid depletion, internal heat and thirst, chronic illness and emaciation, palpitations and insomnia, impotence and cold uterus; heart failure, cardiogenic shock. Used for shortness of breath, palpitations, forgetfulness, thirst and excessive sweating, poor appetite and weakness, all acute and chronic diseases, and shock and collapse caused by blood loss. Greatly replenishes vital energy, consolidates the body, generates fluids, and calms the mind. Treats fatigue and weakness, poor appetite, lethargy, vomiting, loose stools, cough and shortness of breath, spontaneous sweating and sudden collapse, palpitations, forgetfulness, dizziness and headache, impotence, frequent urination, diabetes, metrorrhagia in women, infantile convulsions, and all syndromes of deficiency of qi, blood, and body fluids due to prolonged weakness. The Compendium of Materia Medica states: "It treats all deficiency syndromes in men and women, including fever with spontaneous sweating, dizziness and headache, nausea and vomiting, malaria, chronic diarrhea and dysentery, frequent urination, dribbling urination, internal injuries from overwork, stroke, heatstroke, weakness and paralysis, hematemesis, hemoptysis, hematochezia, hematuria, metrorrhagia, and various prenatal and postpartum diseases." Dosage and administration: For internal use: decoct 5-15 grams, or 15-50 grams for a large dose; it can also be made into a paste, pills, or powder.

[0007] 2. Amomum villosum: Taste and nature: pungent, warm. Meridians: Spleen, Stomach, Kidney. Functions: Resolves dampness and improves appetite, warms the spleen and stops diarrhea, regulates qi and calms the fetus. Indications: Used for dampness obstructing the middle jiao, epigastric fullness and lack of appetite, spleen and stomach deficiency and cold, vomiting and diarrhea, morning sickness, and threatened abortion. Dosage: 3-6 grams, added towards the end of decoction.

[0008] 3. Dried Tangerine Peel: Properties: Warm in nature, pungent and bitter in taste. Meridians: Spleen, Stomach, Lung. Functions: Regulates Qi and strengthens the spleen, harmonizes the middle Jiao, dries dampness, and resolves phlegm. Indications: Abdominal distension or pain due to stagnation of Qi in the spleen and stomach, indigestion. Chest tightness and abdominal distension due to dampness obstructing the middle Jiao, poor appetite and loose stools. Cough and asthma due to phlegm-dampness obstructing the lungs. Used for chest and abdominal distension, poor appetite, vomiting and diarrhea, cough with excessive phlegm. *Compendium of Materia Medica*: "Its function in treating all diseases is to regulate Qi and dry dampness. When combined with tonifying herbs, it tonifies; when combined with purgative herbs, it purges; when combined with ascending herbs, it ascends; when combined with descending herbs, it descends. The spleen is the mother of primordial Qi, and the lungs are the key to controlling Qi; therefore, tangerine peel is essential for the Qi aspect of these two meridians, but its tonifying, purgative, ascending, and descending effects vary depending on the combination." Dosage and Administration: For internal use: decoct 3-10 grams.

[0009] 4. Honeysuckle: Properties: Sweet and cold in nature. Meridians: Lung and Stomach. Functions: Clears heat and detoxifies, reduces inflammation and swelling. Indications: For fever due to exogenous wind-heat or febrile diseases, heatstroke, dysentery due to heat toxins, carbuncles and boils, sore throat, and various infectious diseases. Dosage and administration: For internal use: decoct 10-20g; or make into pills or powders.

[0010] 5. Licorice: Taste and nature: Sweet, neutral. Meridians: Heart, Lung, Spleen, Stomach. Functions: Tonifies the spleen and replenishes qi, clears heat and detoxifies, resolves phlegm and relieves cough, alleviates spasms and pain, harmonizes other herbs. Indications: Weakness of the spleen and stomach, fatigue, palpitations, shortness of breath, cough with excessive phlegm, abdominal and limb spasms and pain, carbuncles and boils, and reduces the toxicity and harshness of other herbs. Dosage and administration: For internal use: Decoction, 2-10 grams.

[0011] 6. Poria cocos: Taste and nature: sweet and bland; neutral. Meridians: Heart, Lung, Spleen, Kidney. Functions: Promotes diuresis and eliminates dampness, strengthens the spleen, and calms the mind. Indications: Used for edema with scanty urine, phlegm retention with dizziness and palpitations, spleen deficiency with poor appetite, loose stools and diarrhea, restlessness, palpitations, and insomnia. Dosage and administration: For internal use: decoct 10-15 grams.

[0012] The above six Chinese herbal medicines form a preventative formula, with ginseng as the chief ingredient, which is sweet and warm, tonifying qi, strengthening the spleen, and nourishing the stomach. The assistant ingredient is cardamom, pungent and warm, which strengthens the spleen, resolves dampness, and improves appetite, enhancing the qi-tonifying and digestive effects; the adjuvant ingredient is poria, sweet and bland, which strengthens the spleen and eliminates dampness. Tangerine peel regulates qi, strengthens the spleen, dries dampness, and resolves phlegm. Honeysuckle clears heat and detoxifies. The guiding ingredient is licorice, which tonifies qi, harmonizes the middle jiao, and balances the effects of all the other herbs. The six herbs work together to tonify qi and strengthen the spleen, thereby enhancing the body's ability to resist external pathogens and achieving the goal of prevention.

[0013] In some embodiments, the compositions of the present invention comprise or consist of the following components:

[0014] 1 to 2 parts by weight of ginseng

[0015] 1 to 2 parts by weight of Amomum villosum,

[0016] Poria cocos 0.8 to 1.5 parts by weight,

[0017] 0.8 to 2 parts by weight of dried tangerine peel

[0018] Honeysuckle, 0.36 to 1.5 parts by weight.

[0019] Licorice 0.6 to 1.8 parts by weight.

[0020] In the embodiments of the present invention, neither reed rhizome nor mulberry leaf, either one or both, are added.

[0021] In some embodiments, the compositions of the present invention comprise or consist of the following components:

[0022] Ginseng 1.2 to 1.5 parts by weight,

[0023] 1.2 to 1.5 parts by weight of Amomum villosum.

[0024] Poria cocos 1 to 1.2 parts by weight,

[0025] 1 to 1.2 parts by weight of dried tangerine peel,

[0026] Honeysuckle 1 to 1.2 parts by weight,

[0027] Licorice 1 to 1.5 parts by weight.

[0028] In some embodiments, the compositions of the present invention comprise or consist of the following components:

[0029] 1 part by weight of ginseng

[0030] 1 part by weight of cardamom

[0031] Poria cocos 0.8 to 1 part by weight,

[0032] 0.8 parts by weight of dried tangerine peel

[0033] Honeysuckle 0.6 parts by weight

[0034] Licorice 0.8 parts by weight.

[0035] In some embodiments, the compositions of the present invention comprise or consist of the following components:

[0036] 1.2 parts by weight of ginseng

[0037] 1 part by weight of cardamom

[0038] 1 part by weight of Poria cocos

[0039] 0.8 parts by weight of dried tangerine peel

[0040] Honeysuckle 0.36 parts by weight,

[0041] Licorice 0.6 parts by weight.

[0042] In some embodiments, the compositions of the present invention comprise or consist of the following components:

[0043] 1 part by weight of ginseng

[0044] 1 part by weight of cardamom

[0045] 0.8 parts by weight of Poria cocos.

[0046] 1 part by weight of dried tangerine peel

[0047] 1 part by weight of honeysuckle

[0048] Licorice 0.8 parts by weight.

[0049] In some embodiments, the particle size of each pharmaceutical component in the composition of the present invention is less than or equal to 60 μm, 50 μm, 25 μm, 20 μm, 15 μm, 10 μm, 9 μm, 8.8 μm, 8.74 μm, 8.7 μm, 8 μm, 7 μm, 6 μm, 5 μm, 2 μm, or 1 μm; preferably 1-10 μm, 1-8.74 μm, or 1-5 μm.

[0050] In some embodiments, the compositions of the present invention are oral compositions, preferably in the form of powders, granules, capsules, or tea bags.

[0051] In some embodiments, the composition of the present invention is a tea bag, wherein the tea bag uses non-woven fabric or cotton cloth to package the composition powder. In some embodiments, the tea bag is further sealed with plastic packaging on top of the non-woven fabric or cotton cloth packaging. In some embodiments, the tea bag is further sealed with plastic packaging on top of the non-woven fabric or cotton cloth packaging and filled with nitrogen.

[0052] In some embodiments, the composition of the present invention is taken after being steeped in boiling water. In some embodiments, the composition of the present invention is taken after being boiled in water for 0.5-2 hours.

[0053] In another aspect, the present invention provides a method for preparing a composition, comprising the following steps:

[0054] Step 1. Dry each component independently;

[0055] Step 2. Crush each dried component and collect the fine powder through a 250-500 mesh sieve, preferably collecting the fine powder through a 300 mesh sieve;

[0056] Step 3. Mix the powders of each component obtained in Step 2;

[0057] Step 4. Weigh the product and prepare the final product.

[0058] In some embodiments, the powder is sieved using 250-mesh, 270-mesh, 300-mesh, 325-mesh, 400-mesh, and 500-mesh sieves in step 2. It is preferable to collect the fine powder that has passed through a 300-mesh sieve.

[0059] In some embodiments, the preparation method of the present invention includes the following steps:

[0060] Step 1. Dry each component independently;

[0061] Step 2. Crush each dried component and collect the fine powder by passing it through a 250-500 mesh sieve, preferably collecting the fine powder that passes through a 300 mesh sieve;

[0062] Step 3. Mix the powders of each component obtained in Step 2;

[0063] Step 4. After weighing, use non-woven fabric or cotton fabric for packaging, with non-woven fabric being preferred;

[0064] Step 5. Seal the package further using plastic packaging.

[0065] In some embodiments, nitrogen filling is optionally used in the sealed plastic packaging of step 5. Nitrogen filling can inhibit or reduce oxidative degradation and improve the storage stability of the composition.

[0066] On the other hand, the present invention provides the use of the composition in the preparation of compositions for preventing influenza virus or coronavirus infection. In some embodiments, the coronavirus is the SARS-CoV-2 virus.

[0067] On the other hand, the present invention provides the use of the said composition in the preparation of a composition for the prevention or treatment of pulmonary fibrosis. In some embodiments, pulmonary fibrosis is caused by influenza virus infection, coronavirus infection, or smoking. In some embodiments, the coronavirus is the SARS-CoV-2 virus.

[0068] definition

[0069] The term "comprising" as used herein means the phrase "including (but not limited to)" and may be used interchangeably with it. The term "including" as used herein means the phrase "including (but not limited to)" and may be used interchangeably with it. Technical solutions using "comprising" or "including" in this patent may be further defined as "comprising" or "forming". In the compositions of the "including" form of this invention, no specific one or both of reed rhizome and mulberry leaf are used.

[0070] The term "parts by weight" as used in this article refers to the relative weight of each component. For example, the relative weight of the components after micronization. Parts by weight can be replaced with "%" of weight. "%" refers to the percentage of the total weight used as the basis for calculating the weight percentage of an individual component. Unless otherwise specified, % refers to weight percentage, and when using mixtures of solids and liquids, it refers to weight-volume percentage.

[0071] The term “or” as used herein means “and / or” and may be used interchangeably with it unless otherwise stated.

[0072] In addition to the numerical values ​​themselves, the numerical values ​​used herein also include ranges of measurement or operational errors acceptable in the art. Unless otherwise defined, the error range of this application may be ±10% of a specific numerical value. Unless otherwise specified, the numerical range in this application covers any integer within that range. Detailed Implementation

[0073] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are one module embodiment of the present invention, and not all embodiments.

[0074] Example 1

[0075] Composition Formulation 1:

[0076] 1 part by weight of ginseng

[0077] 1 part by weight of cardamom

[0078] Poria cocos 0.8 to 1 part by weight,

[0079] 0.8 parts by weight of dried tangerine peel

[0080] Honeysuckle 0.6 parts by weight

[0081] Licorice 0.8 parts by weight.

[0082] Each component was processed according to the following steps:

[0083] Step 1. Dry each component independently;

[0084] Step 2. Crush each dried component and pass it through a 300-mesh sieve to collect the fine powder;

[0085] Step 3. According to the above composition formula, mix the powders of each component obtained in Step 2;

[0086] Step 4. Weigh and then use in non-woven fabric packaging.

[0087] Step 5. Seal the package further using plastic packaging.

[0088] Example 2

[0089] Using the same method as in Example 1, the micro powders of each component were weighed according to the formula in Table 2 and the component-packaged product was prepared.

[0090] Table 2

[0091] Components Formula 2 Formula 3 Formula 4 Formula 5 Ginseng 1 1 1.2 1 Amomum villosum 1 1 1 1 Poria 0.8 1 1 0.8 Dried tangerine peel 0.8 0.8 0.8 1 honeysuckle 0.6 0.6 0.36 1 licorice 0.8 0.8 0.6 0.8

[0092] Example 3: Pharmacodynamic study of the composition in improving pulmonary fibrosis

[0093] This invention uses intratracheal infusion of bleomycin to induce a mouse model of pulmonary fibrosis. A normal control group, a pulmonary fibrosis group, and a group treated with the composition of Formulation 1 in Example 1 were set up. There were 10 mice in the normal control group, 19 mice in the pulmonary fibrosis group, and 19 mice in each of the treatment groups. The effects of the composition of this invention on the prevention and treatment of pulmonary fibrosis were evaluated.

[0094] The composition of Formulation 1 in Example 1 was boiled in water for 2 hours and then cooled to room temperature to obtain an aqueous extract. The aqueous extract was administered to mice in the treatment group by gavage once a day (equivalent to 640 mg / kg of the original powdered drug) for a total of 21 days. The normal control group and the pulmonary fibrosis group were treated by gavage with the same volume of physiological saline under the same conditions.

[0095] At the end of the study, the number of surviving mice in the normal control group, pulmonary fibrosis group, and treatment group were 10, 9, and 12, respectively. The body weight and survival rate of mice in the pulmonary fibrosis group were significantly decreased (P<0.01). The treatment groups treated with the composition of Example 1 showed a significant increase in body weight and survival rate at day 21 (P<0.01), with significantly higher lung weight and lung coefficient in the pulmonary fibrosis group compared to the normal control group, while lung weight and lung coefficient in the treatment group were decreased (P<0.05). Under an optical microscope, the pulmonary fibrosis and collagen content in the pulmonary fibrosis group were significantly higher than in the normal control group. When treated with the composition of Example 1, the level of fibrosis formation in the lungs of the treatment group was reduced. The test results are summarized in Table 2.

[0096] Table 2

[0097] Grouping Average weight (g) Average lung weight (mg) Lung coefficient normal control group 25.00 274.30 11.00 Pulmonary fibrosis group 18.70 413.33 22.23 Drug administration group 21.17 380.50 18.02

[0098] This invention further investigated the expression of E-cadherin and α-SMA in mouse lung tissue. The expression ratios of E-cadherin / β-actin and α-SMA / β-actin in the normal control group, pulmonary fibrosis group, and drug-treated group were measured. The results showed that the drug-treated group increased the protein expression of E-cadherin and inhibited the protein expression of α-SMA in the pulmonary fibrosis group (P<0.01). The test results are summarized in Table 3. The results indicate that the composition of Example 1 affected the transformation of lung epithelial cells into mesenchymal cells in bleomycin-induced pulmonary fibrosis, reduced the E-cadherin-positive area in mouse lung tissue, and almost completely restored the E-cadherin-positive area in lung tissue.

[0099] Table 3

[0100]

Claims

1. A composition, characterized in that, It contains the following ingredients: 1 to 2 parts by weight of ginseng 1 to 2 parts by weight of Amomum villosum, Poria cocos 0.8 to 1.5 parts by weight, 0.8 to 2 parts by weight of dried tangerine peel Honeysuckle, 0.36 to 1.5 parts by weight. Licorice 0.6 to 1.8 parts by weight.

2. The composition according to claim 1, characterized in that... Contains the following ingredients: 1.5 to 2 parts by weight of ginseng. 1.5 to 2 parts by weight of cardamom. Poria cocos 1 to 1.5 parts by weight, 1 to 2 parts by weight of dried tangerine peel Honeysuckle, 1 to 1.5 parts by weight, Licorice 1.2 to 1.8 parts by weight.

3. The composition according to claim 1, characterized in that... The dosage of each component is: 1.2 to 1.5 parts by weight of ginseng. 1.2 to 1.5 parts by weight of Amomum villosum. Poria cocos 1 to 1.2 parts by weight, 1 to 1.2 parts by weight of dried tangerine peel, Honeysuckle 1 to 1.2 parts by weight, Licorice 1 to 1.5 parts by weight.

4. The composition according to claim 1, characterized in that... The dosage of each component is as follows: 1 part by weight of ginseng. 1 part by weight of cardamom Poria cocos 0.8 to 1 part by weight, 0.8 parts by weight of dried tangerine peel Honeysuckle 0.6 parts by weight Licorice 0.8 parts by weight.

5. The composition according to claim 1, characterized in that... The dosage of each component is as follows: 1.2 parts by weight of ginseng 1 part by weight of cardamom 1 part by weight of Poria cocos 0.8 parts by weight of dried tangerine peel Honeysuckle 0.36 parts by weight, Licorice 0.6 parts by weight.

6. The composition according to claim 1, characterized in that... The dosage of each component is as follows: 1 part by weight of ginseng 1 part by weight of cardamom 0.8 parts by weight of Poria cocos. 1 part by weight of dried tangerine peel 1 part by weight of honeysuckle Licorice 0.8 parts by weight.

7. The composition according to any one of claims 1-6, wherein the particle size of each component is less than or equal to 20 μm, preferably less than or equal to 10 μm, 8.47 μm, or 5 μm.

8. The composition of claim 7, wherein the composition is an oral composition, preferably a powder, granules, capsules, or tea bags.

9. The composition of claim 8, wherein the composition is a tea bag packaged in non-woven fabric or cotton fabric.

10. The composition of claim 9, further sealed with plastic packaging on top of nonwoven or cotton packaging, and optionally filled with nitrogen.

11. A method for preparing the composition according to any one of claims 1-10, characterized in that... Includes the following steps: Step 1. Dry each component independently; Step 2. Crush each dried component and collect the fine powder by passing it through a 250-500 mesh sieve; Step 3. Mix the powders of each component obtained in Step 2 according to the proportions of each component in the composition of any one of claims 1-10; Step 4. Weigh the product and prepare the final product.

12. The preparation method according to claim 11, characterized in that... Includes the following steps: Step 1. Dry each component independently; Step 2. Crush each dried component and collect the fine powder by passing it through a 250-500 mesh sieve; Step 3. Mix the powders of each component obtained in Step 2 according to the amounts of each component in any one of claims 1-10; Step 4. After weighing, use non-woven or cotton fabric for packaging; Step 5. Further seal the plastic packaging, optionally using nitrogen filling in the sealed plastic packaging.

13. Use of the composition according to any one of claims 1-10 in the preparation of a composition for the prevention or treatment of pulmonary fibrosis.

14. The use according to claim 13, wherein the pulmonary fibrosis is caused by influenza virus infection or coronavirus infection or smoking; the coronavirus is preferably SARS-CoV-2 virus.

15. Use of the composition of any one of claims 1-10 in the preparation of a composition for the prevention or treatment of pneumonia caused by an influenza virus or a coronavirus, wherein the coronavirus is preferably SARS-CoV-2 virus.

Images